{'52WeekChange': -0.12353921,
 'SandP52WeekChange': None,
 'address1': '1020 Stony Hill Road',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.15,
 'askSize': 1100,
 'averageDailyVolume10Day': 620550,
 'averageVolume': 585953,
 'averageVolume10days': 620550,
 'beta': 1.017665,
 'beta3Year': None,
 'bid': 4.85,
 'bidSize': 1800,
 'bookValue': 0.765,
 'category': None,
 'circulatingSupply': None,
 'city': 'Yardley',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.17,
 'dayLow': 4.81,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.957,
 'enterpriseToRevenue': 4.919,
 'enterpriseValue': 183084256,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '267 395 2119',
 'fiftyDayAverage': 5.608714,
 'fiftyTwoWeekHigh': 11.66,
 'fiftyTwoWeekLow': 3.28,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 29409324,
 'forwardEps': -1.31,
 'forwardPE': -3.7480917,
 'fromCurrency': None,
 'fullTimeEmployees': 221,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.14124,
 'heldPercentInstitutions': 1.0779799,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/optinose.com',
 'longBusinessSummary': 'OptiNose, Inc., a specialty pharmaceutical company, '
                        'focuses on the development and commercialization of '
                        'products for patients treated by ear, nose, and '
                        'throat; and allergy specialists in the United States. '
                        'The company offers XHANCE, a therapeutic product '
                        'utilizing its proprietary optinose exhalation '
                        'delivery system that delivers a topically-acting and '
                        'anti-inflammatory corticosteroid for the treatment of '
                        'chronic rhinosinusitis with and without nasal polyps. '
                        'It is also developing XHANCE, which is in Phase IIIb '
                        'clinical trial for the treatment of chronic '
                        'sinusitis; and OPN-300 for the treatment of '
                        'Prader-Willi syndrome, a rare genetic obesity '
                        'disorder, as well as autism spectrum disorder. The '
                        'company has a license agreement with Currax '
                        'Pharmaceuticals LLC for the commercialization of '
                        'Onzetra Xsail (sumatriptan nasal powder) to treat '
                        'migraine in adults; and Inexia Limited to develop, '
                        'manufacture, import, and sale products containing '
                        'orexin receptor agonist and/or orexin receptor '
                        'positive modulator molecules for the treatment, '
                        'diagnosis, or prevention of human diseases or '
                        'conditions associated primarily with orexin receptor '
                        'agonism and orexin receptor positive modulation. '
                        'OptiNose, Inc. was founded in 2010 and is '
                        'headquartered in Yardley, Pennsylvania.',
 'longName': 'OptiNose, Inc.',
 'market': 'us_market',
 'marketCap': 225399440,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_252053415',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -110035000,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.15,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.03,
 'phone': '267 364 3500',
 'previousClose': 5.25,
 'priceHint': 4,
 'priceToBook': 6.4183006,
 'priceToSalesTrailing12Months': 6.056357,
 'profitMargins': -2.95658,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.17,
 'regularMarketDayLow': 4.81,
 'regularMarketOpen': 5.15,
 'regularMarketPreviousClose': 5.25,
 'regularMarketPrice': 5.15,
 'regularMarketVolume': 446346,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 45906200,
 'sharesPercentSharesOut': 0.144,
 'sharesShort': 6612000,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 5584697,
 'shortName': 'OptiNose, Inc.',
 'shortPercentOfFloat': 0.2791,
 'shortRatio': 10.52,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'OPTN',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.557,
 'twoHundredDayAverage': 5.5897484,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '9935cfef-8b2d-350a-a595-96d5fb99e4f0',
 'volume': 446346,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.optinose.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '19067'}